CVE:HEM Hemostemix (HEM) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free HEM Stock Alerts C$0.04 +0.01 (+12.50%) (As of 04/26/2024 05:33 PM ET) Add Compare Share Share Today's RangeC$0.04▼C$0.0550-Day RangeC$0.04▼C$0.1052-Week RangeC$0.04▼C$0.18Volume32,000 shsAverage Volume45,488 shsMarket CapitalizationC$4.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesInsider TradesStock AnalysisChartHeadlinesInsider Trades Get Hemostemix alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Hemostemix Stock (CVE:HEM)Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.Read More HEM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HEM Stock News HeadlinesMarch 7, 2024 | finanznachrichten.deHemostemix Inc.: Hemostemix Announces Engagement of Oak Hill Asset Management Inc.March 7, 2024 | finance.yahoo.comHemostemix Announces Engagement of Oak Hill Asset Management Inc.April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 20, 2024 | theglobeandmail.comHemostemix: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (HEM)February 19, 2024 | theglobeandmail.comHemostemix: Top 10 Undervalued Biotechnology Industry Stocks (HEM)February 6, 2024 | finance.yahoo.comHemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental SciencesJanuary 19, 2024 | morningstar.comHemostemix Inc HMTXFOctober 30, 2023 | finanznachrichten.deHemostemix Inc.: Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart DiseaseApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.October 30, 2023 | finance.yahoo.comHemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart DiseaseOctober 20, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc down on Thursday (HEM)August 29, 2023 | finance.yahoo.comHemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant ApplicationsAugust 8, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc up on Friday (HEM)June 28, 2023 | finanznachrichten.deHemostemix Inc.: Hemostemix Closes $403,539 of the Unit Private PlacementJune 28, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc up on Tuesday (HEM)June 28, 2023 | finance.yahoo.comHemostemix Closes $403,539 of the Unit Private PlacementJune 27, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc down on Monday (HEM)June 24, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc flat on Wednesday (HEM)June 22, 2023 | marketwatch.comHemostemix's Private Placement Use of ProceedsJune 17, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc down on Friday (HEM)June 2, 2023 | msn.comHemostemix to raise $1.2M through private placement of unitsMay 3, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc flat on Tuesday (HEM)May 2, 2023 | finance.yahoo.comHemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant CompanyApril 29, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc flat on Friday (HEM)April 21, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc flat on Thursday (HEM)April 20, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc up on Wednesday (HEM)April 19, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc down on Tuesday (HEM)See More Headlines Receive HEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Next Earnings (Estimated)5/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:HEM CUSIPN/A CIKN/A Webwww.hemostemix.com Phone+1-403-3409207FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-3,170,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-165.67% Debt Debt-to-Equity RatioN/A Current Ratio0.25 Quick Ratio0.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow10.77 Book ValueC($0.08) per share Price / Book-0.56Miscellaneous Outstanding Shares89,790,000Free FloatN/AMarket CapC$4.04 million OptionableNot Optionable Beta0.55 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Thomas A. Smeenk B.A. (Age 62)BA Hons, Co-Founder, President, CEO & Director Comp: $308kMs. Christina Wu CPAInterim Chief Financial OfficerPeter PavlinVice President of OperationsDr. Fraser C. Henderson Sr.M.D., Chief Medical OfficerKey CompetitorsInnovotechCVE:IOTRevive TherapeuticsCVE:RVVQuest PharmaTechCVE:QPTPacgen Life Science Co. (PBS.V)CVE:PBSMedifocus Inc. (MFS.V)CVE:MFSView All CompetitorsInsidersThomas SmeenkBought 20,000 shares on 12/14/2023Total: C$1,400.00 ($0.07/share)Thomas SmeenkBought 13,000 shares on 12/5/2023Total: C$910.00 ($0.07/share)Thomas SmeenkBought 25,000 shares on 11/7/2023Total: C$1,750.00 ($0.07/share)View All Insider Transactions HEM Stock Analysis - Frequently Asked Questions How have HEM shares performed in 2024? Hemostemix's stock was trading at C$0.07 at the beginning of the year. Since then, HEM shares have decreased by 35.7% and is now trading at C$0.05. View the best growth stocks for 2024 here. When is Hemostemix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our HEM earnings forecast. What other stocks do shareholders of Hemostemix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hemostemix investors own include Iplayco (IPC), Capricor Therapeutics (CAPR), Gene Biotherapeutics (CRXM), Camber Energy (CEI), Auxly Cannabis Group (CBWTF), Cannabis Science (CBIS), Beazer Homes USA (BZH), Big Tree Group (BIGG), Asterias Biotherapeutics (AST) and How do I buy shares of Hemostemix? Shares of HEM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:HEM) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemostemix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
